Therapeutics for Covid-19 patients
The invention concerns the use of DNA aptamers that can shield the SARS-CoV-2 binding site on the cell, and halt the cell-to-cell spreading of coronavirus.
New Dendrimeric Pyrrolidines
The invention proposes a new approach to rare genetic diseases for which no cures are available, only symptomatic treatments through the preparation of novel multivalent molecules active toward the human enzymes responsible for them
Antagonism of B3 adrenoceptor for the treatment of cancer immune tolerance
The invention relates to the use of beta-blocking compounds, in particular the antagonist of ?3 adrenoceptor (?3-ARs), for the treatment of immune-tolerance associated with pathological states, such as cancer.
A_Atrofi: New compounds for the treatment of musculoskeletal atrophy and cachexia
The invention is represented by a mixture of molecules, called A_ATROFI, capable of regulating the balance between protein synthesis and its degradation in skeletal muscle cells.
New activators of SIRT1 enzyme for the treatment of cardiovascular and cardiometabolic pathologies
The present invention targets a class of compounds able to activate the enzyme SIRT1 in humans by regulating numerous metabolic functions. The appropriately designed compounds could be used in pharmaceutical formulations, preferably in the treatment or prevention of cardiometabolic diseases
Monoacylglycerol lipase (MAGL) inhibitors
The new patented compounds are based on a potent reversible noncovalent mechanism of action, which is useful for treating MAGL-mediated diseases, such as neuroinflammation/degeneration, pain, multiple sclerosis/amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease.
Highly selective inhibitors of adams activity
The invention concerns the development of appropriately designed and synthesized chemical entities that selectively exert their activity on ADAMs, A Disintegrin And Metalloproteinase (ADAM) enzyme.
Isoindoline derivatives such as AMPK activators
The present invention relates to the development of novel isoindoline derivatives as activators of AMPK (Adenosine MonoPhosphate-activated protein Kinase), a key enzyme in cellular metabolism. The compounds, with original chemical structure, can be usefully employed for the prevention and treatment of metabolic disorders, such as type II diabetes and obesity, as well as immune-mediated inflammatory diseases and cancer.
Benzofuran derivatives as AMPK activators
The present invention relates to the development of novel benzofuran derivatives able to activate AMPK (Adenosine MonoPhosphate-activated protein Kinase), a key enzyme in the regulation of immune homeostasis
BENZO[D]ISOTHIAZOL-3(2H)-ONE-1,1-DIOXIDE core derivatives and their use in the treatment of cancer
The present invention relates to novel benzo[d]isothiazolic-3(2H)-one-1,1-dioxide core compounds able to effectively and selectively inhibiting the IX and XII isoforms of the enzyme carbonic anhydrase (CA), which are predominantly expressed in hypoxic and metastatic tumors.